Clinical decision support system exemption amendments
Regulatory Intelligence Leads should update their compliance checks and monitoring processes to align with the new exemption details effective from 1 November 2026.
Primary source: Safety monitoring and information
The classification rules for non-invasive medical devices that maintain the patency or flush the lumen of another medical device have been updated.
This update impacts regulatory classification, which could alter labeling and compliance processes for combination products, affecting their marketability and safety oversight.
Review and adjust labeling and compliance processes for affected combination products as per the new regulations.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Review and adjust labeling and compliance processes for affected combination products as per the new regulations.
The TGA has announced updated classification rules that may affect non-invasive medical devices used in combination with other devices, potentially altering their regulatory status.
What changed: The classification rules for non-invasive medical devices that maintain the patency or flush the lumen of another medical device have been updated.
Why it matters: This update impacts regulatory classification, which could alter labeling and compliance processes for combination products, affecting their marketability and safety oversight.
Practical implication: Review and adjust labeling and compliance processes for affected combination products as per the new regulations.
Published from the regulator source ingestion pipeline after PV impact triage.
Regulatory Intelligence Leads should update their compliance checks and monitoring processes to align with the new exemption details effective from 1 November 2026.
Review current compliance workflows and adjust processes for monitoring imports under the new packaging rules.
Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.
Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.